AstraZeneca (AZN) Withdraws App for Ovarian-Cancer Treatment in Europe

September 21, 2016 7:43 AM EDT
Get Alerts AZN Hot Sheet
Trade AZN Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

AstraZeneca (NYSE: AZN) is said to have withdrawn its application for approval of cediranib in Europe following a disagreement with regulators.

Bloomberg noted that the action won't affect development of the ovarian cancer treatment.

AstraZeneca filed an application with the European Medicines Agency in June 2015 seeking approval of cediranib for use with platinum-based chemotherapy in adults with a type of ovarian cancer that’s relapsed.

Shares of AstraZeneca are indicated lower Wednesday morning.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

FDA, Trader Talk

Add Your Comment